Definition // The thymic peptide
What Is Thymosin Alpha-1? The Thymic Peptide, Explained
The structure, the origin, the synthetic drug thymalfasin, and the names it travels under — set out plainly.
The gist
Thymosin Alpha-1 (often shortened to Tα1 or the TA1 peptide) is a small protein the body makes naturally. It is built from 28 amino-acid building blocks, with a chemical 'cap' (an acetyl group) on one end that the molecule needs to work. The body cuts it out of a bigger parent protein called prothymosin alpha, mainly in connection with the thymus — the gland that schools the immune system. Scientists worked out its exact sequence in 1977 and later made an identical copy in the lab; that lab-made version is the drug thymalfasin. Its job is to fine-tune immune defenses: it helps the immune system's scout cells brief its specialist cells. It is not a muscle or growth peptide. Levels of it naturally fall as people age and run lower in some long-term inflammatory conditions, which is part of why researchers became interested in giving it as a medicine.
TA1 peptide: structure and identity
The TA1 peptide is a 28-amino-acid, N-terminally acetylated polypeptide with a molecular weight of about 3108.3 Da and CAS number 62304-98-7. Its sequence is highly acidic, with no aromatic residues and no disulfide bonds, and the N-terminal acetylation is essential for biological activity [1]. It is cleaved in the body from the 113-amino-acid precursor prothymosin alpha. Goldstein and colleagues first isolated it from calf thymus, as a component of the preparation called thymosin fraction 5, and determined its complete primary structure [1]. Endogenous levels decline with age and are reduced in some chronic inflammatory and autoimmune conditions — for example, serum Tα1 is significantly lower in psoriatic arthritis, rheumatoid arthritis and systemic lupus erythematosus than in healthy controls [16].
Thymalfasin: the synthetic drug
Thymalfasin is the International Nonproprietary Name for the synthetic, sequence-identical form of Thymosin Alpha-1 used in clinical trials and marketed abroad. It is the same molecule as the endogenous peptide — same 28 residues, same acetylated terminus — manufactured rather than extracted [4]. It is approved in roughly 35 countries, chiefly as an immune modulator for chronic viral hepatitis and as an immune adjuvant, and is supplied as a lyophilized powder for subcutaneous injection [4]. It is not approved for marketing in the United States; US availability is limited to investigational and compounding contexts. Decades of international human data describe it as well tolerated, with mild injection-site reactions as the most common adverse effect [4][17].
The names it travels under
Thymosin Alpha-1 appears in the literature and in research-use circles under several labels, which is part of why it gets confused with other compounds. Tα1 (or the ASCII form Ta1) is the standard scientific shorthand; TA1 peptide and TA-1 are common in research-use contexts; thymosin alpha 1 (without the hyphen) is a frequent spelling. The drug form carries the INN thymalfasin. All of these point to the same 28-amino-acid acetylated thymic peptide with CAS number 62304-98-7 [1]. What they do not include is any of the separately named thymic peptides — thymosin beta-4, thymulin, thymopentin or thymalin — each of which is a distinct molecule with its own sequence and role. When a source uses 'thymosin' loosely, it is worth checking which one is meant, because their biology can diverge sharply, even to the point of opposite immune effects [15].
Where it came from, and why researchers pursued it
The discovery traces to Allan Goldstein and colleagues, who were studying thymosin fraction 5 — a crude mixture of thymic peptides — and isolated Thymosin Alpha-1 as one of its biologically active components, publishing its full sequence in 1977 [1]. The interest was straightforward: the thymus governs immune maturation, its output falls with age, and a defined peptide that could restore immune function had obvious appeal for infections and immune deficiency. By 1990, US clinical trials of thymosins for immune and neuroendocrine modulation were already under way and documented in the literature [14]. The synthetic, sequence-identical thymalfasin followed, and development concentrated on chronic viral hepatitis and immune adjuvant uses, where the evidence has stayed most consistent [4]. The arc from a thymus-extract fraction to a defined, manufacturable peptide is what made decades of controlled study possible.
What it is not
Because several thymic peptides have similar names, it helps to state the boundaries. Thymosin Alpha-1 is not thymosin beta-4 / TB-500 (a 43-amino-acid actin-binding, tissue-repair peptide — the WADA-prohibited one), not thymulin / FTS (a zinc-dependent nonapeptide), not thymopentin / TP-5 (a pentapeptide), and not thymalin (a separate bovine thymic-extract preparation). It is also not the same as prothymosin alpha, which is its larger precursor, not a synonym. And it is not an anabolic, growth or performance compound: it acts on immune cells, and the literature gives no basis for muscle-building claims. If you reached this page from a strength or bodybuilding search, the honest answer is that the science points entirely at immune function — there is no evidence it builds muscle. The careful side-by-side is on the thymosin alpha 1 mechanism of action page.